July 24, 2019
ImaginAb kicks off cancer treatment testing
ImaginAb has started the clinical trial of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells.